Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Russell Patmore

Showing results (31-40 of 39) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 39 results.
British Journal of Haematology|September 14, 2012
Whole genome expression profiling based on paraffin embedded tissue can be used to classify diffuse large B-cell lymphoma and predict clinical outcomeSharon L Barrans, Simon Crouch, Matthew A Care, et al.
BMJ Open|February 23, 2021
Health impact of monoclonal gammopathy of undetermined significance (MGUS) and monoclonal B-cell lymphocytosis (MBL): findings from a UK population-based cohortMaxine Je Lamb, Alexandra Smith, Daniel Painter, et al.
Blood|October 18, 2002
Flow cytometric disease monitoring in multiple myeloma: the relationship between normal and neoplastic plasma cells predicts outcome after transplantationAndy C Rawstron, Faith E Davies, Ranjit DasGupta, et al.
Haematologica|January 29, 2026
Male sex adversely impacts survival and myeloid malignancy risk in MGUS: a real-world population-based studyEve Roman, Timothy Bagguley, Simon Crouch, et al.
British Journal of Haematology|November 12, 2025
COVID-19-related mortality in a real-world cohort of 18 883 patients with premalignant and malignant haematological neoplasms: An analysis from the UK's Haematological Malignancy Research NetworkAlexandra Smith, Clare Frobisher, Abraham Varghese, et al.
Ejhaem|July 18, 2022
Favourable outcomes for high-risk Burkitt lymphoma patients (IPI 3-5) treated with rituximab plus CODOX-M/IVAC: Results of a phase 2 UK NCRI trialElizabeth H Phillips, Catherine Burton, Amy A Kirkwood, et al.
Blood|March 19, 2020
Targeted sequencing in DLBCL, molecular subtypes, and outcomes: a Haematological Malignancy Research Network reportStuart E Lacy, Sharon L Barrans, Philip A Beer, et al.
Blood Advances|April 1, 2022
Molecular subclusters of follicular lymphoma: a report from the United Kingdom's Haematological Malignancy Research NetworkSimon Crouch, Daniel Painter, Sharon L Barrans, et al.
British Journal of Haematology|February 23, 2021
Ibrutinib for mantle cell lymphoma at first relapse: a United Kingdom real-world analysis of outcomes in 211 patientsRory McCulloch, David Lewis, Nicola Crosbie, et al.
Pageof 4

Showing results (31-40 of 39) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 39 results.
British Journal of Haematology|September 14, 2012
Whole genome expression profiling based on paraffin embedded tissue can be used to classify diffuse large B-cell lymphoma and predict clinical outcomeSharon L Barrans, Simon Crouch, Matthew A Care, et al.
BMJ Open|February 23, 2021
Health impact of monoclonal gammopathy of undetermined significance (MGUS) and monoclonal B-cell lymphocytosis (MBL): findings from a UK population-based cohortMaxine Je Lamb, Alexandra Smith, Daniel Painter, et al.
Blood|October 18, 2002
Flow cytometric disease monitoring in multiple myeloma: the relationship between normal and neoplastic plasma cells predicts outcome after transplantationAndy C Rawstron, Faith E Davies, Ranjit DasGupta, et al.
Haematologica|January 29, 2026
Male sex adversely impacts survival and myeloid malignancy risk in MGUS: a real-world population-based studyEve Roman, Timothy Bagguley, Simon Crouch, et al.
British Journal of Haematology|November 12, 2025
COVID-19-related mortality in a real-world cohort of 18 883 patients with premalignant and malignant haematological neoplasms: An analysis from the UK's Haematological Malignancy Research NetworkAlexandra Smith, Clare Frobisher, Abraham Varghese, et al.
Ejhaem|July 18, 2022
Favourable outcomes for high-risk Burkitt lymphoma patients (IPI 3-5) treated with rituximab plus CODOX-M/IVAC: Results of a phase 2 UK NCRI trialElizabeth H Phillips, Catherine Burton, Amy A Kirkwood, et al.
Blood|March 19, 2020
Targeted sequencing in DLBCL, molecular subtypes, and outcomes: a Haematological Malignancy Research Network reportStuart E Lacy, Sharon L Barrans, Philip A Beer, et al.
Blood Advances|April 1, 2022
Molecular subclusters of follicular lymphoma: a report from the United Kingdom's Haematological Malignancy Research NetworkSimon Crouch, Daniel Painter, Sharon L Barrans, et al.
British Journal of Haematology|February 23, 2021
Ibrutinib for mantle cell lymphoma at first relapse: a United Kingdom real-world analysis of outcomes in 211 patientsRory McCulloch, David Lewis, Nicola Crosbie, et al.
Pageof 4